期刊
SCIENTIFIC REPORTS
卷 12, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-26821-8
关键词
-
资金
- Deutsche Forschungsgemeinschaft (DFG
- German Research Foundation) [452622720, TR240 374031971]
- DFG [192904750, CRC 992, FOR 2674-2]
- Projekt DEAL
Treatment of myelodysplastic syndromes with decitabine is crucial, and early platelet response can predict overall survival. However, the effect of decitabine on megakaryocytes and bone marrow needs further investigation.
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however, is understudied. We show that an early platelet increment was not detectable in healthy mice during decitabine treatment. Analyses of bone marrow sections revealed vessels with dilated lumina, decreased cellularity, but increased number of red blood cells and the presence of (pro)platelet-like particles. Taken together, decitabine treatment of healthy mice does not induce an early platelet increment, but affects the bone marrow.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据